NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma, a biotech company focused on treating nervous system damage, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference, with President & CEO Mike Kelly presenting on August 13, 2024. Alongside the in-person event, a webcast will be available for broader access. The company continues to progress with its lead drug candidate, NVG-291, aimed at enabling nervous system repair.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
